MENU
+Compare
BOLD
Stock ticker: NASDAQ
AS OF
Apr 11 closing price
Price
$1.22
Change
+$0.03 (+2.52%)
Capitalization
27.21M

BOLD Boundless Bio Forecast, Technical & Fundamental Analysis

Boundless Bio Inc is a clinical-stage oncology company... Show more

Industry: #Biotechnology
BOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for BOLD with price predictions
Apr 11, 2025

Momentum Indicator for BOLD turns negative, indicating new downward trend

BOLD saw its Momentum Indicator move below the 0 level on March 26, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator turned negative. In of the 13 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for BOLD turned negative on April 04, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BOLD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BOLD entered a downward trend on April 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BOLD's RSI Oscillator exited the oversold zone, of 10 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

BOLD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.181) is normal, around the industry mean (13.293). P/E Ratio (0.000) is within average values for comparable stocks, (62.876). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.750). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (244.810).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BOLD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BOLD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
BOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

BOLD is expected to report earnings to rise 37.84% to -101 cents per share on May 19

Boundless Bio BOLD Stock Earnings Reports
Q1'25
Est.
$-1.02
Q4'24
Beat
by $0.10
Q3'24
Missed
by $0.01
Q2'24
Missed
by $0.12
The last earnings report on March 27 showed earnings per share of -74 cents, beating the estimate of -83 cents. With 87.39K shares outstanding, the current market capitalization sits at 27.21M.
A.I. Advisor
published General Information

General Information

a developer of gene therapy products for patients with serious rare diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
9880 Campus Point Drive
Phone
+1 858 766-9912
Employees
72
Web
https://www.boundlessbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ENHCX9.760.14
+1.46%
Cullen Enhanced Equity Income C
ALCBX11.30N/A
N/A
ALPS/Smith Balanced Opportunity C
KNPAX129.92N/A
N/A
Kinetics Paradigm Adv A
HIGUX18.59N/A
N/A
Carillon Eagle Growth & Income R6
JANIX23.01N/A
N/A
Janus Henderson Triton D

BOLD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BOLD has been loosely correlated with PRME. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if BOLD jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BOLD
1D Price
Change %
BOLD100%
+2.52%
PRME - BOLD
35%
Loosely correlated
+13.68%
DSGN - BOLD
33%
Loosely correlated
+3.58%
DNA - BOLD
33%
Poorly correlated
+11.23%
ETXPF - BOLD
32%
Poorly correlated
N/A
KYMR - BOLD
32%
Poorly correlated
+7.68%
More